**INTRODUCTION**

Ankylosing spondylitis (AS) is a chronic and multisystem inflammatory rheumatic disease with spinal and extra-skeletal features, which mainly affects the joints of the axial skeleton. AS is characterized by tissue inflammation with structural damage and fibrosis, and the limited activity and persistent pain may lead to a poor quality of life during the active disease. It has suggested that intracellular cytokines, inflammatory cells, and inflammatory chemokines were associated with the pathogenesis of structural damage and fibrosis in patients with AS.

Galectin-3 is a member of soluble β-galactoside-binding lectin, which plays an important role in the development of inflammation and fibrosis. Previous studies have shown that increased galectin-3 expression was observed in various cancer cells. Recently, the increased expression of galectin-3 has been suggested in autoimmune diseases such as systemic sclerosis, Behcet’s disease, and rheumatoid arthritis. These studies indicated that serum

**Objective:** The aim of our study was to assess potential correlations between serum galectin-3 concentrations and Ankylosing Spondylitis Disease Activity (ASDAS) index in patients with ankylosing spondylitis (AS).

**Methods:** A total of 112 patients with AS were included, and 130 healthy subjects were considered as controls. We collected the detailed medical history, and ASDAS index was used to assess the disease severity in patients with AS.

**Results:** The serum galectin concentrations were higher in AS patients compared to the health groups (14.1 ± 9.6 vs 9.2 ± 3.7, \( P < 0.001 \)). The correlation analysis showed that serum galectin concentrations were significantly positively correlated with C-reactive protein and erythrocyte sedimentation rate (\( r = 0.369, P < 0.001; r = 0.240, P = 0.011 \)). In addition, the positively correlation of serum galectin-3 with global pain index (\( r = 0.238, P = 0.011 \)) was observed in AS patients. A significant positively correlation between serum galectin and ASDAS index in AS patients was found (\( r = 0.367, P < 0.001 \)). In multiple linear regression analysis, the results indicated that increased serum galectin still was correlated with ASDAS index (\( r = 0.322, P = 0.001 \)) in patients with AS.

**Conclusions:** Serum galectin concentrations were found to be correlated with ASDAS index in patients with AS.

**KEYWORDS**

ankylosing spondylitis, ASDAS index, serum galectin-3
galectin-3 might be associated with the pathogenesis and progression of rheumatic disease. Therefore, the aim of our study was to assess the potential correlation of serum galectin-3 levels and ASDAS index in patients with AS.

2 | MATERIALS AND METHODS

2.1 | Participants

A total of 112 patients with AS were included, and 130 healthy subjects were considered as controls in this study. The AS patients were diagnosed according to the modified New York criteria. Patients were excluded as follows: coronary heart disease, active infection, diabetes, polycystic ovary syndrome, liver and kidney disease and tumors. We collected the detailed history of all participants, and ASDAS index was used to assess the disease severity in patients with AS, the formula is: $0.121 \times \text{back pain} + 0.058 \times \text{morning stiffness} + 0.110 \times \text{overall patient assessment} + 0.073 \times \text{peri‐}

2.2 | Clinical and biochemical assessment

Laboratory indexes such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were measured by standard laboratory methods. Serum was collected and frozen at −80°C at refrigerator for the galectin-3 measurement. Afterward, serum galectin-3 concentrations were tested with a commercially available enzyme-linked immuno‐

2.3 | Statistical analysis

SPSS 20.0 (Chicago, IL, USA) was used for all statistical analyses, and the results were taken as statistically significant if two‐sided $P < 0.05$. The comparisons between AS patients and control groups were performed by using t tests or Mann-Whitney U tests for continuous variables, and chi-square test for categorical variables. We used the Spearman correlation to identify correlations between serum galectin-3 and laboratory tests. A stepwise multiple linear regression analysis was used to assess the correlation between the serum galectin-3 and ASDAS index in patients with AS.

3 | RESULTS

3.1 | Clinical and laboratory characteristics

The demographic and clinical data are shown in Table 1. The age, sex, and body mass index were matched between the AS patients and healthy controls. The mean values for the ASDAS index were $3.4 \pm 1.6$ in patients with AS. Compared to control groups, the levels of the CRP and ESR were higher in patients with AS. Moreover, the serum galectin-3 levels were higher in AS patients compared to the health groups ($14.1 \pm 9.6$ vs $9.2 \pm 3.7$, $P < 0.001$).

3.2 | The correlation coefficients in patients with AS

The correlation analysis showed that serum galectin-3 concentrations were significantly positively correlated with CRP and ESR ($r = 0.369$, $P < 0.001$; $r = 0.240$, $P = 0.011$) in patients with AS. A significant positively correlation between serum galectin-3 and ASDAS index in AS patients was found ($r = 0.367$; $P < 0.001$, Figure 1). In addition, the positive correlations of serum galectin-3 with global pain index ($r = 0.238$, $P = 0.011$) were observed in AS patients.

3.3 | The multiple linear regression analysis between serum galectin-3 and ASDAS index in AS patients

In multiple linear regression analysis, the variables in age, sex, smoking, body mass index, family history, disease duration, ESR, CRP, global pain index, and ASDAS index were included as independent variables; the results indicated that increased serum galectin-3 concentrations still were correlated with ASDAS index ($r = 0.322$, $P < 0.001$) in patients with AS, and the additional correlations of serum galectin-3 with CRP and ESR ($r = 0.173$, $P = 0.041$; $r = 0.354$, $P < 0.001$) were observed in AS patients, as shown in Table 2.

**Table 1** The main data characteristics in AS patients and healthy controls

|                          | AS patients | Healthy controls |
|--------------------------|-------------|------------------|
| n                        | 112         | 130              |
| Gender (F/M)             | 21/91       | 23/107           |
| Age (y)                  | $31.8 \pm 9.6$ | $29.8 \pm 13.4$ |
| Smoking (n, %)           | 25 (22.3%)  | 28 (21.5%)       |
| Body mass index (kg/m²)  | $23.1 \pm 2.9$ | $22.7 \pm 3.6$  |
| Family history of AS (n, %) | 8 (7.1%) | 0 (0%)           |
| Disease duration (y)     | 4.0 ± 5.1   | -                |
| NSAID                    | 110 (98.2%) | -                |
| Sulfasalazine            | 43 (38.4%)  | -                |
| Corticosteroid           | 5 (4.5%)    | -                |
| ASDAS index              | 3.4 ± 1.6   | -                |
| Global pain index        | 50.3 ± 24.1 | -                |
| Erythrocyte sedimenta‐tion rate (mm/h) | $19.3 \pm 13.4$ | $5.7 \pm 3.2$  |
| C-reactive protein (mg/L) | $16.3 \pm 13.1$ | $1.7 \pm 2.0$  |
| Serum galectin-3 (ng/mL) | $14.1 \pm 9.6$ | $9.2 \pm 3.7$   |

**Table amended from CAO et al.**
factor-α and interleukin-6, and galectin-3 gene deficiency can reduce the development of experimental autoimmune encephalomyelitis. Second, galectin-3 can activate myofibroblasts and promote fibrosis, galectin-3 can promote inflammatory cytokine secretion in tissue fibroblasts, and galectin-3 is a critical mediator of transforming growth factor-β-induced pulmonary fibrosis. Third, the galectin-3 gene expression is increased in inflammatory tissues in patients with juvenile idiopathic arthritis, and the gene expressions of galectin-3 are elevated in immune cell in systemic lupus erythematosus patients. Therefore, inflammation and immune dysfunction may increase serum galectin-3 levels in patients with AS, and these pathological changes corporately contribute to the progression of disease in AS patients.

Several potential limitations should be considered. First, we did not evaluate the effects of drugs on serum galectin-3 levels such as NSAID, sulfasalazine, and corticosteroid. Second, we did not observe the expression of galectin-3 in pathological tissue sections in patients with AS. Third, our study was a small sample, so the results needed to be further replicated with larger sample. Despite of these limitations, serum Gal-3 concentrations were found to be correlated with ASDAS index in patients with AS, indicating serum galectin may be a useful biomarker to assess the disease activity in AS patients.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

ORCID

Ya-Bin Hu https://orcid.org/0000-0002-2940-2711

REFERENCES

1. van der Linden SM, van der Heijde D, Maksymowych WP. Ankylosing spondylitis. In: Firestein GS, Budd RC, Harris Jr ED et al., eds. Kelley’s Textbook of Rheumatology. Philadelphia, PA: Elsevier Saunders Press;2009:1169-1189.
2. Ozdemir O. Quality of life in patients with ankylosing spondylitis: relationships with spinal mobility, disease activity and functional status. *Rheumatol Int*. 2011;31(5):605-610.
3. Braun J, Sieper J. Ankylosing spondylitis. *Lancet*. 2007;369:1379-1390.
4. Feltkamp TE, Mardjuadi A, Huang F, Chou CT. Spondyloarthropathies in eastern Asia. *Curr Opin Rheumatol*. 2001;13:285-290.
5. Xie Z, Wang P, Li J et al. MCP1 triggers monocyte dysfunctions during abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis. *J Mol Med (Berl)*. 2017;95(2):143-154.
6. Zhu J, Lin X, Huang F. Th1/Th2 balances and ankylosing spondylitis. *Chin J Rheumatol*. 2000;4:202-205.
7. De Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. *Eur J Heart Fail*. 2009;11(9):811-817.
8. Darrow AL, Shohet RV. Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes. *Cardiovasc Diabetol*. 2015;6(14):73.
9. Yilmaz H, Celik HT, Ozdemir O, et al. Serum galectin-3 levels in women with PCOS. *J Endocrinol Invest*. 2014;37(2):181-187.
10. Van den Brûle F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. *Glycoconj J*. 2002;19(7–9):537–542.

11. Faludi R, Nagy G, Tökés-Füzesi M, Kovács K, Czirják L, Komócsi A. Galectin-3 is an independent predictor of survival in systemic sclerosis. *Int J Cardiol*. 2017;233:118–124.

12. Lee YJ, Kang SW, Song JK, et al. Galectin-3 and galectin-3 binding protein levels in Behçet’s disease and their association with disease activity. *Clin Exp Rheumatol*. 2007;25(4 Suppl 45):S41–S45.

13. Ohshima S, Kuchen S, Seemayer CA, et al. Galectin 3 and its binding protein in rheumatoid arthritis. *Arthritis Rheum*. 2003;48(10):2788–2795.

14. Goie The HS, Steven MM, Van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. *Br J Rheumatol*. 1985;24:242–249.

15. Sellas I, Fernandez A, Juanola Roura X, Alonso RA. Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). *Rheumatol Int*. 2017;37(11):1817–1823.

16. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. *J Am Coll Cardiol*. 2012;60(14):1249–1256.

17. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. *Proc Natl Acad Sci U S A*. 2006;103(13):5060–5065.

18. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. *Am J Respir Crit Care Med*. 2012;185(5):537–546.

19. Nielsen CT, Østergaard O, Rekvig OP, Sturfelt G, Jacobsen S, Heegaard NH. Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis. *Lupus*. 2015;24(11):1150–1160.

20. Forsman H, Islander U, Andréasson E, et al. Galectin 3 aggravates joint inflammation and destruction in antigen-induced arthritis. *Arthritis Rheum*. 2011;63(2):445–454.

21. Jiang HR, Al Rasebi Z, Mensah-Brown E, et al. Galectin-3 deficiency reduces the severity of experimental autoimmune. *J Immunol*. 2009;182(2):1167–1173.

22. Filer A, Bik M, Parsonage GN, et al. Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways. *Arthritis Rheum*. 2009;60(6):1604–1614.

23. MacKinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of Transforming Growth Factor-β1–Driven Lung Fibrosis by Galectin-3. *Am J Respir Crit Care Med*. 2012:185(5):537–546.

24. Harjacek M, Díaz-Can S, De Miguel M, Wolfe H, Maldonado CA, Rabinovich GA. Expression of galectins-1 and -3 correlates with defective mononuclear cell apoptosis in patients with juvenile idiopathic arthritis. *J Rheumatol*. 2001;28(8):1914–1922.

25. Kang EH, Moon KC, Lee EY, et al. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. *Lupus*. 2009;18(1):22–28.